Literature DB >> 18419478

Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study.

Junxia Yao1, Clemens Bechter, Markus Wiesneth, Georg Härter, Marlies Götz, Lothar Germeroth, Philippe Guillaume, Ferishte Hasan, Stephanie von Harsdorf, Thomas Mertens, Detlef Michel, Hartmut Döhner, Donald Bunjes, Michael Schmitt, Anita Schmitt.   

Abstract

BACKGROUND: Cytomegalovirus (CMV) disease represents a serious complication after allogeneic peripheral blood stem cell (PBSC) transplantation. If possible, stem cell donors for transplantation are selected on the basis of their CMV serostatus. However, the cytomegalovirus-specific immune status can be further characterized by measuring CMV phosphoprotein 65-specific CD8(+) T cell frequencies using tetramers, pentamers, and streptamers. We therefore investigated the specificity and sensitivity of all 3 methods and compared the results to patient serostatus.
METHODS: Twenty-three samples from CMV-seropositive healthy volunteers and 15 samples from CMV-seropositive patients before and after allogeneic PBSC transplantation were stained with tetramers, pentamers, or streptamers and analyzed by flow cytometry.
RESULTS: Similar frequencies of CD8(+) and multimer(+) T cells could be measured by all 3 multimer technologies. The lowest background signals (< or =0.02%) were obtained using tetramer technology. Frequencies of 0.19%-2.48% of CMV phosphoprotein 65 495-503-specific CD8(+) T cells were detected in healthy volunteers. Antigen-specific T cells were detected in only 11 (48%) of 23 seropositive healthy volunteers. CMV antigenemia before day 100 after allogeneic PBSC transplantation occurred in 2 of 3 patients without any specific T cells.
CONCLUSION: These findings demonstrate the power of multimer staining and a certain limitation of serologic testing to define appropriate donors for transplantation. Therefore, whenever possible, CMV-seropositive donors of transplants to seropositive recipients should be screened for their CD8(+) T cell frequency. All 3 multimer technologies can be used, yielding similar results. The streptamer technology additionally offers the advantage of selecting CMV phosphoprotein 65-specific CD8(+) T cells at the good manufacturing practice level for adoptive T cell transfer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18419478     DOI: 10.1086/587749

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

Authors:  Corinna La Rosa; Jeffrey Longmate; Chetan Raj Lingaraju; Qiao Zhou; Teodora Kaltcheva; Nicola Hardwick; Ibrahim Aldoss; Ryotaro Nakamura; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-16       Impact factor: 5.742

Review 2.  Immunotherapy for transplantation-associated viral infections.

Authors:  Claire Roddie; Karl S Peggs
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

3.  Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples.

Authors:  Joseph D Tario; George L Chen; Theresa E Hahn; Dalin Pan; Rosemary L Furlage; Yali Zhang; Liselotte Brix; Charlotte Halgreen; Kivin Jacobsen; Philip L McCarthy; Paul K Wallace
Journal:  Cytometry B Clin Cytom       Date:  2014-10-23       Impact factor: 3.058

4.  Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cells.

Authors:  Coen Govers; Cor Berrevoets; Elike Treffers-Westerlaken; Marieke Broertjes; Reno Debets
Journal:  Hum Gene Ther Methods       Date:  2012-06       Impact factor: 2.396

5.  Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation.

Authors:  Sylvia Borchers; Melanie Bremm; Thomas Lehrnbecher; Elke Dammann; Brigitte Pabst; Benno Wölk; Ruth Esser; Meral Yildiz; Matthias Eder; Michael Stadler; Peter Bader; Hans Martin; Andrea Jarisch; Gisbert Schneider; Thomas Klingebiel; Arnold Ganser; Eva M Weissinger; Ulrike Koehl
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

Review 6.  Cellular-based immunotherapies for patients with glioblastoma multiforme.

Authors:  Xun Xu; Florian Stockhammer; Michael Schmitt
Journal:  Clin Dev Immunol       Date:  2012-02-28

7.  Targeted in-vitro-stimulation reveals highly proliferative multi-virus-specific human central memory T cells as candidates for prophylactic T cell therapy.

Authors:  Benjamin Faist; Fabian Schlott; Christian Stemberger; Kevin M Dennehy; Angela Krackhardt; Mareike Verbeek; Götz U Grigoleit; Matthias Schiemann; Dieter Hoffmann; Andrea Dick; Klaus Martin; Martin Hildebrandt; Dirk H Busch; Michael Neuenhahn
Journal:  PLoS One       Date:  2019-09-30       Impact factor: 3.240

8.  Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry.

Authors:  Britta Eiz-Vesper; Britta Maecker-Kolhoff; Rainer Blasczyk
Journal:  Front Immunol       Date:  2013-01-28       Impact factor: 7.561

9.  Impaired functionality of antiviral T cells in G-CSF mobilized stem cell donors: implications for the selection of CTL donor.

Authors:  Carola E Bunse; Sylvia Borchers; Pavankumar R Varanasi; Sabine Tischer; Constança Figueiredo; Stephan Immenschuh; Ulrich Kalinke; Ulrike Köhl; Lilia Goudeva; Britta Maecker-Kolhoff; Arnold Ganser; Rainer Blasczyk; Eva M Weissinger; Britta Eiz-Vesper
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

10.  Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8+ T cells.

Authors:  Fabian Schlott; Dominik Steubl; Stefanie Ameres; Andreas Moosmann; Stefan Dreher; Uwe Heemann; Volker Hösel; Dirk H Busch; Michael Neuenhahn
Journal:  PLoS One       Date:  2018-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.